2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-179293
    SARS-CoV-2 PLpro-IN-3
    SARS-CoV-2 PLpro-IN-3 (Compound 15) is a covalent inhibitor of the SARS-CoV-2 papain-like protease (PLpro), with an IC50 of 25 nM. SARS-CoV-2 PLpro-IN-3 has similar inhibitory activity against SARS-CoV PLpro (IC50 = 59 nM), but shows no inhibitory effect on human ubiquitin-specific protease 7 (USP7). The EC50 of SARS-CoV-2 PLpro-IN-3 in inhibiting SARS-CoV-2 replication in cells is 96 nM, significantly reducing the viral titer and viral RNA levels. SARS-CoV-2 PLpro-IN-3 can be used for studying SARS-CoV-2 drug resistance mutations.
    SARS-CoV-2 PLpro-IN-3
  • HY-179297
    FM-678 2754280-83-4
    FM-678 is a fungicidal agent. FM-678 demonstrates exceptional efficacy against P. pachyrhizi with an EC50 of 0.14 mg/L.
    FM-678
  • HY-179334
    DMA-155 2237925-69-6
    DMA-155 is an antiviral agent with binding activity against SARS-CoV-2 5'-terminal stem-loop RNAs, with affinities of 51.1 μM (SL1), 61.1 μM (SL4), 54.5 μM (SL5a), 66.9 μM (SL5b) and 48.6 μM (SL6), respectively. DMA-155 inhibits SARS-CoV-2 viral replication and reduces SARS-CoV-2 viral RNA levels. DMA-155 is applicable to the research of COVID-19.
    DMA-155
  • HY-179367
    AR-102 free acid 955007-30-4
    AR-102 free acid, an active metabolite of AR-102 (HY-19885), is a prostaglandin F (PGF) derivative.
    AR-102 free acid
  • HY-179389
    XDS-23 98%
    XDS-23 is a selective biofilm inhibitor with an IC50 of 1.26 µM against Pseudomonas aeruginosa. XDS-23 exerts a dual inhibitory effect on the LasI/LasR System (las) and Pseudomonas Quinolone Signal System (pqs). XDS-23 suppress the production of key virulence factors including elastase, pyocyanin, and extracellular polysaccharides. XDS-23 exhibits synergistic antibacterial activity and can enhance the efficacy of multiple antibiotics in both in vitro and in vivo models, while maintaining a favorable safety profile. XDS-23 can be employed for research in combating biofilm-mediated drug-resistant P. aeruginosa infections.
    XDS-23
  • HY-179451
    Apoptosis inducer 53 98%
    Apoptosis inducer 53 is an apoptosis inducer. Apoptosis inducer 53 can inhibit proliferation of human tumor cell lines (A549, HeLa, SW1573, T-47D, WiDr) with GI50 values of 2.5-9.1 μM. Apoptosis inducer 53 can induce cancer cells apoptosis and reduce colony formation. Apoptosis inducer 53 can activate p38α MAPK signaling and exerts anti-inflammatory effect. Apoptosis inducer 53 also shows anti-Leishmania donovani activity. Apoptosis inducer 53 can be used for the researches of cancer, infection and inflammation.
    Apoptosis inducer 53
  • HY-179463
    BKI 1708 2332840-70-5
    BKI 1708 is a potent and orally active calcium-dependent protein kinase 1 (CDPK1) inhibitor (IC50 = 0.7 nM). BKI 1708 exhibits potent activity against Neospora (IC50 = 481 nM) and Toxoplasma (IC50 = 122 nM). BKI-1708 induces the formation of multinucleated complexes. BKI-1708 efficiently inhibits vertical transmission of both parasites and increases pup survival in mice.
    BKI 1708
  • HY-179469
    KR-27452 98%
    KR-27452 is a selective and orally active PI4KIIIβ inhibitor with an IC50 of 0.026 μM, while showing no activity against PI4KIIIα (IC50 >10 μM) . KR-27452 specifically binds to and inhibits PI4KIIIβ, leading to reduced viral replication in cells. KR-27452 exhibits strong antiviral activity against human rhinovirus (RVs) and Coxsackievirus (COXs). KR-27452 can be used for the research of infection.
    KR-27452
  • HY-179482
    Anti-Influenza agent 9
    Anti-Influenza agent 9 (Compound 3p) is a M2-S31N mutant influenza virus ion channel blocker. Anti-Influenza agent 9 exhibits inhibitory activity against both M2-WT and M2-S31N viruses, with its EC50 values being 0.92 and 0.55 μM respectively. Anti-Influenza agent 9 can be used in influenza research.
    Anti-Influenza agent 9
  • HY-179529
    EGFR/InhA-IN-1
    EGFR/InhA-IN-1 (Compound 15) is an inhibitor of the anti-cancer target EGFR tyrosine kinase (1M17) (Ki = 0.05 μM) and the anti-tuberculosis target InhA enzyme (1OUZ) (Ki = 0.02 μM). EGFR/InhA-IN-1 exhibits anti-proliferative activity against A549 cells, with an IC50 of 10.38 μM. EGFR/InhA-IN-1 has inhibitory activity against Mycobacterium tuberculosis H37Rv, with a MIC of 6.25 μM. EGFR/InhA-IN-1 can be used for research on non-small cell lung cancer and Mycobacterium tuberculosis infection.
    EGFR/InhA-IN-1
  • HY-179556
    SARS-CoV-2 nsp14-IN-10
    SARS-CoV-2 nsp14-IN-10 is a highly potent and selective NSP14 (IC50 = 0.34 µM) S-adenosylmethionine (SAM) binding pocket inhibitor. SARS-CoV-2 nsp14-IN-10 demonstrates robust antiviral activity against SARS-CoV-2. SARS-CoV-2 nsp14-IN-10 exhibits broad-spectrum activity against other betacoronaviruses and inhibits SARS-CoV-2 at the replication stage. SARS-CoV-2 nsp14-IN-10 suppresses viral translation and exhibits immunostimulatory effects. SARS-CoV-2 nsp14-IN-10 specifically reverses NSP14-mediated alterations inhost transcriptome. SARS-CoV-2 nsp14-IN-10 can be used for the study of SARS-CoV-2.
    SARS-CoV-2 nsp14-IN-10
  • HY-179567
    NVP-EGT710 2893895-11-7 98%
    NVP-EGT710 (EGT710) is an orally active non-peptidomimetic covalent SARS-CoV-2 Mpro inhibitor. NVP-EGT710 can be used for coronavirus infection research.
    NVP-EGT710
  • HY-179586
    HIV-1-IN-91
    HIV-1-IN-91 (Compound BAN) is a HIV-1 protease inhibitor.
    HIV-1-IN-91
  • HY-179618
    NDM-1-IN-11
    NDM-1-IN-11 is a potent covalent NDM-1 inhibitor with an IC50 of 1.12 μM, which acts by forming a Se-S bond with the enzyme. NDM-1-IN-11 effectively suppresses the growth of NDM-1-producing E. coli in both in vivo and in vitro models when combined with Meropenem (HY-13678). NDM-1-IN-11 can be used for addressing NDM-1 driven bacterial resistance.
    NDM-1-IN-11
  • HY-179634
    ASF-006 sodium 98%
    ASF-006 sodium, a tetrapodal tryptophan derivative, is a potent viral invasion inhibitor. ASF-006 sodium shows potent antiviral activity against different SARS-CoV-2 Omicron variants but not against the ancestral SARS-CoV.2 strain (Wuhan-Hu-1). ASF-006 sodium competitively inhibits receptor-binding domain (RBD)-ACE2 binding via an allosteric mechanism. ASF-006 sodium inhibits Omicron BA.1, Omicron XBB.1.5, respiratory syncytial virus (RSV) and Ebola virus infection with IC50s of 0.02 μM, 0.3 μM, 1.52 μM and 0.2 μM, respectively. ASF-006 sodium inhibits cell entry of both HIV and enterovirus A71[1].
    ASF-006 sodium
  • HY-179637
    RNAP-σ interaction-IN-4 98%
    RNAP-σ interaction-IN-4 (Compound 3a) is an inhibitor of the RNA polymerase-sigma factor interaction (RNAP-σ) with MIC values against S. pneumoniae and S. aureus of 1 μg/mL and 2 μg/mL, respectively. RNAP-σ interaction-IN-4 exhibits strong bactericidal properties by interfering with the interaction of β′CH−σ and disrupting the transcription of bacteria. RNAP-IN-2 shows significant efficacy in sepsis models. RNAP-σ interaction-IN-4 can be used to study Gram-positive bacterial infections caused by multi-drug resistant strains.
    RNAP-σ interaction-IN-4
  • HY-179638
    Antiviral agent 74 3059641-72-1 98%
    Antiviral agent 74 is an antiviral agent consisting of Cidofovir (HY-17438) prodrug and lipid chain. Antiviral agent 74 can inhibit the activity of viral DNA polymerase by transforming into Cidofovir.Antiviral agent 74 demonstrates potent antiviral activity against vacciniavirus (VACV) (EC50 = 0.156 μM) comparable to Brincidofovir (HY-14532). Antiviral agent 74 shows superior potency against monkeypox virus (MPXV) with an EC50 vales of 0.202 μM. Antiviral agent 74 can be used for the research of virus infection.
    Antiviral agent 74
  • HY-179649
    sALT629 484026-63-3 98%
    sALT629 is an orally active antitubercular agent with potent intramacrophage activity (EC50 = 1.5 μM). sALT629 shows broad-spectrum anti-Mycobacterium tuberculosis (Mtb) activities across four carbon sources, equipotent efficacy against drug-resistant Mtb, and activity against both slow-replicating and nonreplicating Mtb. sALT629 exhibits synergistic activity when combined with oxazolidinone drugs, such as Linezolid (HY-10394) and Sutezolid (HY-10392). sALT629 can be used for the research of tuberculosis.
    sALT629
  • HY-179656
    UA2239 2455422-89-4
    UA2239 is an antimalarial agent and acyclic nucleoside phosphonate. UA2239 disrupts the essential cGMP-dependent egress pathway by decreasing cGMP levels. UA2239 targets guanylyl cyclase α. UA2239 demonstrates rapid and irreversible inhibitory effects on Plasmodium parasites.
    UA2239
  • HY-179673
    Antitubercular agent-54 98%
    Antitubercular agent-54 is an antitubercular agent with potent intramacrophage activity (EC50 = 0.68 μM). Antitubercular agent-54 shows a MIC of 0.31 μM against Mycobacterium tuberculosis (Mtb) H37Rv in cholesterol-containing medium. Antitubercular agent-54 can be used for the research of tuberculosis.
    Antitubercular agent-54
Cat. No. Product Name / Synonyms Application Reactivity